Which is better, sitagliptin or metformin?

Sitagliptin and metformin are two drugs commonly used to treat type 2 diabetes, and each has its own advantages. Metformin is an oral hypoglycemic drug that effectively reduces blood sugar levels by reducing hepatic glucose production and increasing tissue utilization of glucose, while having a small impact on body weight. Sitagliptin is a DPP-4 inhibitor that regulates blood sugar by increasing GLP-1 levels. Compared with metformin, the advantage of sitagliptin is that it has a relatively mild hypoglycemic effect and is less likely to cause hypoglycemia, making it suitable for some patients who are sensitive to hypoglycemia. Furthermore, sitagliptin is generally well tolerated and requires relatively little renal function. The choice between sitagliptin and metformin is usually individualized by the physician based on the patient's specific circumstances and needs. Some patients may find a more suitable treatment regimen between these two drugs, and sometimes a combination strategy is adopted to enhance the hypoglycemic effect. Patients should closely follow their doctor's recommendations when selecting and using medications, and conduct regular monitoring and follow-up visits.